Trial reportAmerican journal of perinatology2015
Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes.
Trial report in American journal of perinatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2026Pooled it
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2024Pooled it
- Maternal and neonatal outcomes following magnesium sulfate in the setting of chorioamnionitis: a meta-analysis.Archives of gynecology and obstetrics · 2024Pooled it
- Tocolytics for delaying preterm birth: a network meta-analysis (0924).The Cochrane database of systematic reviews · 2022Pooled it
- Maintenance tocolysis in twin pregnancies after preterm premature rupture of membranes and neonatal outcomes: a retrospective cohort study.BMC pregnancy and childbirth · 2026Article
- Malignant Hypertension Complicated by Posterior Reversible Encephalopathy Syndrome (PRES).Case reports in medicine · 2025Article
- Expectant Management of PPROM Improves Neonatal Outcome-A Retrospective Study of 562 Patients.Journal of clinical medicine · 2021Article
- The effect of antenatal magnesium sulfate on intraventricular hemorrhage in premature infants: a systematic review and meta-analysis.Obstetrics & gynecology science · 2020Article
- Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.Fluids and barriers of the CNS · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 16 institutions in 1 country.
Funding
Abstract
objectiveThis study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 31(6/7) weeks' gestation. STUDY
designThis is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 31(6/7) weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death.
resultsA total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7%, p = 0.51). Delivery < 7 days was similar between groups (55.4 and 51.4%, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p = 0.29). Composite neonatal outcomes did not differ between groups.
conclusionMagnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.